- Conditions
- Alzheimers Disease
- Interventions
- RO7126209, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 15
- States / cities
- Atlantis, Florida • Clermont, Florida • Lady Lake, Florida + 12 more
Condition Directory
Alzheimer's Disease clinical trials
Directory of U.S. ClinicalTrials.gov public records for Alzheimer's Disease. Browse Alzheimer's Disease recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 2, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
43
Shown on this page
12
Current sort
Recently updated
Condition scope
Alzheimer's Disease
Additional filters apply within this condition.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Alzheimer's Disease studies are organized in the registry
The registry typically spells this condition “Alzheimer disease” (without the apostrophe-s), and both spellings appear across listings. Early-stage research uses its own vocabulary — prevention and early-intervention studies are often filed under “mild cognitive impairment,” “prodromal,” or “preclinical” rather than the disease name, and some enroll cognitively healthy volunteers at elevated risk. This directory also has a dedicated mild cognitive impairment page.
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 1–12 of 43 matching trials for Alzheimer's Disease.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Preclinical Alzheimer's Disease, Alzheimer Disease, Prodromal Alzheimer's Disease
- Interventions
- AADvac1, Tau2
- Drug
- Lead sponsor
- Paul S. Aisen
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- San Francisco, California • Providence, Rhode Island • Nashville, Tennessee
- Conditions
- Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease
- Interventions
- AADvac1, Donanemab
- Drug
- Lead sponsor
- Paul S. Aisen
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- San Francisco, California • Providence, Rhode Island • Nashville, Tennessee
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease
- Interventions
- Senicapoc, Placebo Tablet
- Drug · Other
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- Sacramento, California • Walnut Creek, California
- Conditions
- Alzheimer's Disease
- Interventions
- Placebo, Bepranemab
- Other · Biological
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 466 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 40
- States / cities
- Fresno, California • Fullerton, California • Irvine, California + 34 more
- Conditions
- Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease, Alzheimer's Disease
- Interventions
- Placebo (Study Part 1a), ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a, ACI-24.060 at Dose C in Study Part 1a, ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b, Placebo (Study Part 2), ACI-24.060 at Dose A in Study Part 2, ACI-24.060 at Dose B in Study Part 2, ACI-24.060 at Dose C in Study Part 2, Placebo (Study Part 1b), ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b
- Biological
- Lead sponsor
- AC Immune SA
- Industry
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Lady Lake, Florida • Orlando, Florida + 9 more
- Conditions
- Alzheimer Disease
- Interventions
- LY3372689, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 327 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 35
- States / cities
- Canoga Park, California • Fresno, California • Irvine, California + 30 more
- Conditions
- Prodromal Alzheimer's Disease
- Interventions
- Partnered Rhythmic Rehabilitation (PRR), Group walking (WALK)
- Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Early Alzheimer's Disease
- Interventions
- Lecanemab IV, Placebo, Lecanemab SC
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 1,906 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 112
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 84 more
- Conditions
- Prodromal Alzheimer's Disease, Mild Cognitive Impairment, Subjective Cognitive Complaints
- Interventions
- Digital Memory Notebook (DMN) Application
- Behavioral
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Aging
- Interventions
- repetitive transcranial magnetic stimulation (rTMS)
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Prodromal Alzheimer's Disease, Preclinical Alzheimer's Disease, Healthy Aging, Cognitive Decline
- Interventions
- Active rTMS, Sham rTMS
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 40 Years to 99 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
About this Alzheimer's Disease clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Alzheimer's Disease as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Alzheimer's Disease.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Alzheimer's Disease.